Pain Adversely Affects Outcomes to a Collaborative CareIntervention for Anxiety in Primary Care
Natalia E. Morone, MD, MS1,2,7, Bea Herbeck Belnap, Dr. Biol. Hum1,7, Fanyin He, BS3,Sati Mazumdar, PhD3, Debra K. Weiner, MD2,4,5,6,7, and Bruce L. Rollman, MD, MPH1,7
1Division of General Internal Medicine, Center for Research on Health Care, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA;2Geriatric Research Education and Clinical Center, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, USA; 3Department ofBiostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA; 4Division of Geriatrics, University of PittsburghSchool of Medicine, Pittsburgh, PA, USA; 5Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA;6Department of Anesthesiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 7Clinical and Translational SciencesInstitute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
BACKGROUND: Primary care patients with PanicDisorder (PD) and Generalized Anxiety Disorder(GAD) experience poorer than expected clinical out-comes, despite the availability of efficacious pharma-cologic and non-pharmacologic treatments. A barrierto recovery from PD/GAD may be the co-occurrence ofpain.OBJECTIVE: To evaluate whether pain intensity inter-fered with treatment response for PD and/or GAD inprimary care patients who had received collaborativecare for anxiety disorders.DESIGN: A secondary data analysis of a randomized,controlled effectiveness trial comparing a telephone-delivered collaborative care intervention for primarycare patients with severe PD and/or GAD to theirdoctors usual care.PARTICIPANTS: Patients had to have a diagnosis of PDand/or GAD and a severe level of anxiety symptoms.The 124 patients randomized at baseline to the collab-orative care intervention were analyzed. Participantswere divided into two pain intensity groups based ontheir response to the SF-36 Bodily Pain scale (none ormild pain vs. at least moderate pain).MAIN MEASURES: Pain was assessed using the BodilyPain scale of the SF-36. Anxiety symptoms weremeasured with the Hamilton Anxiety Rating Scale(HRS-A), Panic Disorder Severity Scale (PDSS) andGeneralized Anxiety Disorder Severity Scale (GADSS).Measures were collected over 12 months.KEY RESULTS: At baseline, patients with at leastmoderate pain were significantly more likely to endorsemore anxiety symptoms on the HRS-A than patientswith no pain or mild pain (P
Unfortunately, primary care patients with PD and GADexperience poorer than expected clinical outcomes, despitethe availability of efficacious pharmacologic and non-pharmacologic treatments that primary care providers(PCP) can provide.1520 A variety of explanations for thisinclude PCPs unfamiliarity with guideline-based treatmentsused in specialty care settings,21 patient resistance to apsychiatric diagnosis,22,23 and insufficient patient adherenceto treatment recommendations. However, an additionalbarrier to recovery from PD/GAD may be the co-occurrenceof pain. This finding has been well-described in depressedpatients, as they are less likely to respond to treatment ifthey have comorbid pain, but has not been well-studied inpatients with PD and/or GAD.2426 To evaluate whetherpain intensity interfered with recovery from comorbid PDand/or GAD, we studied primary care patients who hadparticipated in a trial of collaborative care (CC) for anxietydisorders.27 Our objective was to describe the prevalence ofcomorbid pain among study participants with PD and/orGAD, and to determine the impact of pain on our CCintervention. Our primary hypothesis was that patients withPD and/or GAD and at least moderate pain were signifi-cantly less likely to respond to the CC intervention thanpatients with PD and/or GAD and mild or no pain.
We performed a secondary data analysis on the ReduceLimitations from Anxiety (RELAX) Trial: a randomized,controlled effectiveness trial comparing a telephone-deliv-ered CC intervention for primary care patients with PD and/or GAD to their doctors usual care.27 Trained caremanagers delivered an intervention for anxiety. Outcomemeasures were obtained from January 2005December2008. The study was approved by the University ofPittsburgh Institutional Review Board, and all patientsprovided written informed consent.
The trial recruited from six primary care practices within theUniversity of Pittsburgh Medical Center.28 If patients had: aPrimary Care Evaluation of Mental Disorders (PRIME-MD)1
diagnosis of PD and/or GAD and severe anxiety symptoms,defined as a Panic Disorder Severity Scale (PDSS)29 score14 or a Hamilton Anxiety Rating Scale (HRS-A)30 score 20 respectively; medical stability; life expectancy > 1 year;no active suicidality; no history of bipolar disorder, alcoholdependence or substance abuse; were not in treatment with amental health specialist (MHS); were English speaking; hadno communication barrier, and owned a household tele-phone, they were randomized to either a telephone-deliveredCC intervention or their PCPs usual care for anxiety.33
These analyses focused on the patients randomized atbaseline to the CC intervention (n=124).
ProceduresCollaborative Care Intervention. The intervention lastedfor 12 months and consisted of several components.
1. Patients randomized to CC were initially contacted by acare manager via telephone to review treatment optionsof guided education (bibliotherapy), pharmacotherapy,referral to a MHS, or some combination thereof. CCwas directed toward treatment of anxiety and paintreatment information was not collected (such asparticipation in physical therapy or injections).
2. When a patient selected bibliotherapy, a workbook foreither managing PD31 or GAD32 (depending on theirdiagnosis or preference if they had both conditions) wasmailed to them. If the patient agreed to pharmacother-apy, the care manager reviewed the patients pastanxiolytic medications.
3. At weekly case review meetings with the clinical team(made-up of a general internist, psychiatrist, andpsychologist), the care manager presented all newlyenrolled patients. For all other patients, they presentedthe patients progress. The clinical team would thenmake recommendations based on the patients treatmentresponse.33 Additionally, if the patients symptoms werenot improving, they needed additional psychiatricsupport, or if they voiced interest in seeing a MHS,the care manager facilitated appointments to a MHS.The PCP was informed about the recommendedchanges via the electronic medical record (EMR). Allmedications were prescribed by the PCP.
4. Patients were initially contacted every 2 weeks for theacute phase of treatment, which included assessing forsymptom development, medication side effects (ifindicated), following up on a recommendation to see aMHS (if made), and review of the workbook. The acutephase usually lasted 4 months.
5. The acute phase of treatment concluded when thepatients anxiety symptoms improved to at least mildseverity. The patient then entered the continuation phaseof treatment, during which the care manager typicallycontacted the patient once a month. Should the patientssymptoms relapse, he or she would return to the acutephase of treatment.
The diagnoses for the clinical trial were abstracted bytrained study nurses from the problem list of the EMR, andassigned a category based on a systems approach if thecondition had persisted over at least 6 months. NEM reviewed
59Morone et al.: Pain Affects Anxiety OutcomesJGIM
each patients list of potentially painful and chronic conditionsto confirm the accuracy of the nurse-led chart abstractions, aswell as to additionally classify the patient as having a painfulcondition. The painful conditions fell into the followingcategories: musculoskeletal, gastrointestinal, genitourinary,neurological/sensory, migraine/chronic headaches, and chronicpain syndrome. In addition to sociodemographic information,the following measures were obtained at baseline, 2, 4, 8, and12 months by a trained assessor blinded to treatmentassignment. The Panic Disorder Severity Scale29 and Gener-alized Anxiety Disorder Severity Scale34 were only adminis-tered to patients with PD or GAD, respectively.
1. Medical Outcomes Study 36-Item Short Form HealthSurvey (SF-36): Pain was assessed using the BodilyPain scale of the widely used SF-36.35 Higher scoresindicate better health related quality of life and lessbodily pain. The Mental Component Summary (MCS)score was also reported.
2. Primary Care Evaluation of Mental Disorders (PRIME-MD) Patient Health Questionnaire (PHQ): The Anxietyand Mood Modules were administered to patients toestablish the diagnoses of PD, GAD, and majordepression.36 It has a sensitivity of 57 % and a specificityof 9799 % for both PD and GAD, compared to thegold standard of a MHSs clinical interview (sensitivity69 %, specificity 82 % for depression).36
3. Hamilton Rating Scale for Anxiety (HRS-A): This scalemeasures the subjective severity of anxiety symptomswithin the preceding 7 days.30 It has long been used asan indicator for anxiolytic efficacy in PD37 and GAD.38
The parent study adopted Bechs convention, whereintotal HRS-A scores of 20+ indicate severe anxiety.37
Lower scores are better.4. Panic Disorder Severity Scale (PDSS): This scale
assesses the overall severity of panic symptoms.29,39 Ithas been used as an outcome measure in other clinicaltrials of treatments for PD,40 including those in primarycare settings.16,27,33 Lower scores are better.
5. Generalized Anxiety Disorder Severity Scale (GADSS):This scale assesses the severity of GAD symptoms. It hasbeen shown to have high internal consistency, validity,and sensitivity to chang